


Financial Results of the 2nd Quarter for Fiscal Year Ending June 2025

February 14, 2025



(Securities code: 7747 Prime of Tokyo Stock Exchange,
Premier of Nagoya Stock Exchange)

FYE June 2025 Q2 YTD Main Points - 1

Revenue 61,491 Mil.Yen <Year-on-year +13.2%>

Progressed favorably primarily Medical Division(domestic/overseas) due to expanding demands and exchange rate fluctuation.

■ Medical Division ~Progressed favorably both Cardiovascular and Non-cardiovascular fields~

- External environment : Increased revenue due to the exchange rate fluctuation (Yen depreciation)
Limited impact due to the reimbursement of price deduction
- Cardiovascular field: Increased in all regions mainly PCI GW and Penetration Catheter
- Non-Cardiovascular field: Increased in all fields such as Neurovascular, Peripheral vascular, Abdominal vascular, and gastrointestinal.
- OEM business: Decreased mainly in US

■ Device Division ~Decreased in both industrial components and medical components ~

- External environment : Increased in revenue due to the exchange rate fluctuation (Yen depreciation)
- Medical Components: Decreased due to decreased Cardiovascular inspection catheter components for US companies.
- Industrial Components: Decreased in overseas leisure-related transactions despite increasing in construction-related in Japan

□ Impact of increased revenue due to exchange rate fluctuation (Yen depreciation) +1,654 Mil. Yen

FYE June 2025 Q2 YTD Main Points - 2

Operating income 17,395 Mil. Yen <YoY +28.9%>

Improvement in gross profit margin is progressing more than expected.

Operating income increased significantly despite increasing SGA, etc.

■ **Gross profit: 41,549 Mil.Yen < YoY +18.1% >**

- Increased in gross profit due to increased in revenue and gross profit margin (64.8%→67.6%)

■ **Operating income excluding goodwill amortization, etc.: 18,402 Mil. Yen < YoY +27.1% >**

■ **Operating income: 17,395 Mil.Yen <YoY +28.9% >**

- Increased in sales-related expenses both domestically and overseas due to increased revenue and strengthened promotional activities.
- Increased in R&D expenses (5,820 Mil.Yen) (YoY +515 Mil.Yen, R&D-to-Revenue ratio 9.5 %)
- Goodwill amortization, etc. (1,007Mil.Yen) (YoY +22 Mil.Yen)

■ **Ordinary income: 16,821 Mil.Yen <YoY +24.9% >**

- Non-operating expenses: Increased in foreign exchange loss (YoY +677 Mil.Yen)

■ **Net Income attributable to parent company shareholders: 12,261 Mil.Yen <YoY +24.9% >**

- Extraordinary income: Reversal of allowance for doubtful accounts (YoY +100 Mil.Yen)

Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2025 Q2 YTD	151.00	163.37	21.00	4.39
FYE June 2024 Q2 YTD	146.35	158.20	20.20	4.14

Highlights Year-on-Year

	FYE June 2024 Q2 YTD		FYE June 2025 Q2 YTD			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	YoY	
					Changes (Mil.Yen)	Changes (%)
Revenue	54,341	100.0	61,491	100.0	+7,149	+13.2
Gross Profit	35,191	64.8	41,549	67.6	+6,358	+18.1
Operating Income excluding goodwill amortization, etc.	14,484	26.7	18,402	29.9	+3,918	+27.1
Operating Income	13,498	24.8	17,395	28.3	+3,896	+28.9
Ordinary Income	13,471	24.8	16,821	27.4	+3,350	+24.9
Net income attributable to parent company shareholders	9,820	18.1	12,261	19.9	+2,441	+24.9
EPS (yen)	36.15	—	45.14	—	+8.99	+24.9
EBITDA	18,258	33.6	22,710	36.9	+4,452	+24.4

(Reference) At the same exchange rate as the previous year			
Amount (Mil.Yen)	Ratio (%)	YoY	
		Changes (Mil.Yen)	Changes (%)
Revenue	100.0	+5,494	+10.1*
Gross Profit	67.8	+5,404	+15.4
Operating Income excluding goodwill amortization, etc.	29.7	+3,291	+22.7
Operating Income	28.1	+3,293	+24.4

* After adjusting for lump-sum sales in the previous fiscal year and excluding the impact of foreign exchange rates: YoY +12.1%

Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2025 Q2 YTD	151.00	163.37	21.00	4.39
FYE June 2024 Q2 YTD	146.35	158.20	20.20	4.14

Revenue by Segment Year-on-year

	FYE June 2024 Q2 YTD		FYE June 2025 Q2 YTD			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	Changes (Mil.Yen)	Changes (%)
Medical	48,369	89.0	55,763	90.7	+7,393	+15.3
Device	5,972	11.0	5,727	9.3	-244	-4.1
Total amount	54,341	100.0	61,491	100.0	+7,149	+13.2

(Reference)


Medical Field	52,227	96.1	59,551	96.8	+7,324	+14.0
Device Field	2,114	3.9	1,940	3.2	-174	-8.3

Operating Income by Segment Year-on-year

	FYE June 2024 Q2 YTD		FYE June 2025 Q2 YTD			
	Amount (Mil.Yen)	Operating margin (%)	Amount (Mil.Yen)	Operating margin (%)	Changes (Mil.Yen)	Changes (%)
Operating income excluding goodwill amortization, etc.						
Medical	15,011	31.0	19,525	35.0	+4,514	+30.1
Device	2,875	48.2	2,457	42.9	-417	-14.5
Erasing & Head Quarters *	-3,403	—	-3,581	—	-177	+5.2
Total	14,484	26.7	18,402	29.9	+3,918	+27.1
Operating income						
Medical	14,026	29.0	18,518	33.2	+4,492	+32.0
Device	2,875	48.2	2,457	42.9	-417	-14.5
Erasing & Head Quarters *	-3,403	—	-3,581	—	-177	+5.2
Total	13,498	24.8	17,395	28.3	+3,896	+28.9
(Reference)						
Device Division Segment Revenue	6,761	—	7,288	—	+527	+7.8

※ Due to organizational expansion at some overseas subsidiaries, etc., the attribution of administrative costs has been changed from Medical/Device segments to Headquarters segment from FYE June 2025. Therefore, the figures adjusted to reflect the allocation of administrative costs for the period FYE June 2024 in line with FYE June 2025. (Correction effect in FYE June 2024 Q2 Medical Division -827, Device Division -268 ⇒Erasing/Head quarters +1,096)


Earnings Performance by Segment



※ Due to organizational expansion at some overseas subsidiaries, etc., the attribution of administrative costs has been changed from Medical/Device segments to Headquarters segment from FYE June 2025. Therefore, the figures adjusted to reflect the allocation of administrative costs for the period FYE June 2024 in line with FYE June 2025. (Correction effect in FYE June 2024 Q2 Medical Division -827, Device Division -268 ⇒Erasing/Head quarters +1,096)


Attribution Analysis of Operating Income – 1

(Exchange Rate Fluctuations Included)




Attribution Analysis of Operating Income – 2

(Exchange Rate Fluctuations Excluded)



Situation Per Segment Division

Per Segment by Medical Division (by Geography-1)



【Revenue (YoY)】

~ Increased due to expanding market share and exchange rate fluctuation ~

- Japan : Limited impact due to reimbursement price and increased primarily Non-cardiovascular field

- Cardiovascular field : Increased in mainly in Penetration Catheter/Guiding Catheter/PCI GW
- Non-cardiovascular field : Increased in Neurovascular due to the effect of new product and increased in purchased products in Peripheral vascular (Penumbra)

- Overseas : Increased in all regions due to expanding market share and exchange rate fluctuation

- US: Brand products is progressing favorably despite decreasing in OEM transactions (Brand products, YoY up +13.4%)

- Cardiovascular field : Increased in mainly in PCI GW/Penetration Catheter
- Non-cardiovascular field : Increased in all fields including Peripheral and Neurovascular products, primarily in Abdominal vascular products.
- OEM Business: Decreased in transactions due to business partner trends

- Europe: Due to the lump-sum sale of Eastern Europe in Q1 of the previous year, superficially a slight increased. (After adjustment of lump-sum sales YoY +12.3%)

- Cardiovascular field : Increased PCI GW and Penetration catheter.

- China: Significantly increased even excluding its impact owing to increased by replenishment of inventory (forward shipments) at the distributors

- Cardiovascular field : Increased in PCI GW, Balloon Catheter (purchased products) and Penetration Catheter
- Non-cardiovascular field : Increased in Neurovascular products
- OEM Business : Decreased in transactions due to business partner trends

- Other: Progressed overall

- Cardiovascular field : Increased in PCI GW mainly in Asia
- Non-cardiovascular field : Increased in Neurovascular/Abdominal vascular mainly in Asia

【Operating Income】

Operating income increased in proportion to revenue


*In accordance with discussions with the audit firm, the charges of GPO (Group Purchasing Organizations) in US regions is recorded quarterly as negative sales from FYE June 2025. (Q2 Amount -208 Mil.Yen)

Per Segment by Medical Division (by Geography-2)

(Mil. Yen)		FYE June 2024 Q2 YTD	FYE June 2025 Q2 YTD	YoY	
				Changes	Changes (%)
Exchange rate (Yen)	USD	146.35	151.00	+4.65	+3.2
	EURO	158.20	163.37	+5.17	+3.3
	CNY	20.20	21.00	+0.80	+4.0
Total Revenue		48,369	55,763	+7,393	+15.3
Japan		7,247	7,866	+619	+8.5
Overseas		41,122	47,897	+6,774	+16.5
US		10,604	11,130	+525	+5.0
Europe		11,243	11,555	+312	+2.8
China		12,182	16,546	+4,364	+35.8
Other		7,091	8,664	+1,572	+22.2
Operating income		14,026	18,518	+4,492	+32.0

※ Due to organizational expansion at some overseas subsidiaries, etc., the attribution of administrative costs has been changed from Medical/Device segments to Headquarters segment from FYE June 2025. Therefore, the figures adjusted to reflect the allocation of administrative costs for the period FYE June 2024 in line with FYE June 2025. (Correction effect in FYE June 2024 Q2 Medical Division -827, Device Division -268 ⇒Erasing/Head quarters +1,096)


Per Segment by Medical Division (by Treatment-1)



Per Segment by Medical Division (by Treatment-2)

(Mil. Yen)		FYE June 2024 Q2 YTD	FYE June 2025 Q2 YTD	YoY	
				Changes	Changes(%)
Exchange rate (Yen)	USD	146.35	151.00	+4.65	+3.2
	EURO	158.20	163.37	+5.17	+3.3
	CNY	20.20	21.00	+0.80	+4.0
Total Revenue		48,369	55,763	+7,393	+15.3
	Japan	7,247	7,866	+619	+8.5
	Overseas	41,122	47,897	+6,774	+16.5
	Cardiovascular	36,300	42,390	+6,089	+16.8
	Japan	4,134	4,282	+147	+3.6
	Overseas	32,165	38,107	+5,942	+18.5
	Non-Cardiovascular	7,635	9,506	+1,871	+24.5
	Japan	2,107	2,701	+594	+28.2
	Overseas	5,528	6,805	+1,277	+23.1
	OEM	4,434	3,866	-567	-12.8
	Japan	1,005	882	-122	-12.2
	Overseas	3,428	2,984	-444	-13.0

Per Segment by Device Division-1



【Revenue (YoY)】

~Decreased both medical components and industrial components due to the business partner trends~

Medical Component

- Japan : Decreased in Catheter components and robotics-related components transactions
- Overseas : Decreased in inspection catheter components of Cardiovascular for US despite increasing in respiratory catheter components

Industrial Component

- Japan : Increased in construction-related transactions
- Overseas : Decreased in Leisure-related transaction despite increasing OA equipment transactions

【Operating income】

Decreased due to decreased external revenue

Per Segment by Device Division-2

(Mil. Yen)		FYE June 2024 Q2 YTD	FYE June 2025 Q2 YTD	YoY	
				Changes	Changes (%)
Exchange rate (Yen)	USD	146.35	151.00	+4.65	+3.2
Total Revenue		5,972	5,727	-244	-4.1
	Japan	1,430	1,396	-34	-2.4
	Overseas	4,541	4,331	-210	-4.6
	Medical Components	3,857	3,787	-69	-1.8
	Japan	588	513	-75	-12.8
	Overseas	3,268	3,274	+5	+0.2
	Industrial Components	2,114	1,940	-174	-8.3
	Japan	841	882	+41	+4.9
	Overseas	1,273	1,057	-215	-17.0
	Operating income	2,875	2,457	-417	-14.5
	(Reference) Segment Revenue	6,761	7,288	+527	+7.8

※ Due to organizational expansion at some overseas subsidiaries, etc., the attribution of administrative costs has been changed from Medical/Device segments to Headquarters segment from FYE June 2025. Therefore, the figures adjusted to reflect the allocation of administrative costs for the period FYE June 2024 in line with FYE June 2025. (Correction effect in FYE June 2024 Q2 Medical Division -827, Device Division -268 ⇒Erasing/Head quarters +1,096)


Reference: P/L

	FYE June 2024 Q2 YTD		FYE June 2025 Q2 YTD			
	Amount (Mil. Yen)	Ratio (%)	Amount (Mil. Yen)	Ratio (%)	Changes (Mil. Yen)	Main comparison factors
Revenue	54,341	100.0	61,491	100.0	+7,149	•Progressed favorably mainly overseas revenue
Cost of sales	19,150	35.2	19,941	32.4	+791	
Gross profit	35,191	64.8	41,549	67.6	+6,358	•Increased in proportion to increasing revenue and gross profit margin
SGA	21,693	39.9	24,154	39.3	+2,461	•Increased in sales-related and R&D expenses, etc.
Operating income excl. goodwill amortization	14,484	26.7	18,402	29.9	+3,918	
Operating income	13,498	24.8	17,395	28.3	+3,896	
Non-operating income	301	0.6	442	0.7	+141	
Non-operating expense	328	0.6	1,016	1.7	+687	•Increased in foreign exchange losses
Ordinary income	13,471	24.8	16,821	27.4	+3,350	
Extraordinary income	—	—	123	0.2	+123	•Reversal of allowance for doubtful accounts
Extraordinary loss	99	0.2	-	-	-99	•Decreased in loss on valuation of investment securities
Net income attributable to parent company shareholders	9,820	18.1	12,261	19.9	+2,441	
Comprehensive income	9,700	17.9	12,501	20.3	+2,800	

Reference: B/S

		FYE June 2024 Results		FYE June 2025 Q2 YTD			
		Amount (Mil. Yen)	Ratio (%)	Amount (Mil. Yen)	Ratio (%)	Changes (Mil. Yen)	Main comparison factors
Assets	Current assets	94,696	49.4	92,994	48.9	-1,702	Cash and deposits +1,906 Notes and accounts receivable -1,115 Inventories -2,329
	Fixed assets	96,917	50.6	97,135	51.1	+218	
Total assets		191,614	100.0	190,130	100.0	-1,484	
Liabilities	Current liabilities	29,494	15.4	19,801	10.4	-9,693	Short-term borrowings -4,033 Provision for bonuses -1,101 Other -6,074
	Fixed liabilities	10,157	5.3	11,405	6.0	+1,247	Long-term borrowings +903
Total liabilities		39,652	20.7	31,207	16.4	-8,445	
Total net assets		151,961	79.3	158,923	83.6	+6,961	Retained earnings +6,728 Foreign currency Translation adjustment + 640
Total liabilities & net assets		191,614	100.0	190,130	100.0	-1,484	

Reference: C/F



Caution Regarding Information Presented

All forward looking statements contained herein, including revenue forecasts, outlooks, and strategic plans, are based on the best currently available data; however, risk and uncertainty are involved in these statements.

Please note that actual results may differ greatly from plans presented here.

【 IR contact 】

Asahi Intecc Co., Ltd.
corporate strategic office

TEL 0561-48-5551

URL <https://www.asahi-intecc.co.jp/en>